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Abstract 
Over the last decade, multiple studies have attempted to identify better risk prediction tools 
specific to the chronic kidney disease (CKD) population. In many cases, these studies have 
evaluated the use of various peptide biomarkers as prediction tools. This is common practice 
in clinical medicine, but in CKD patients these studies are complicated by the fact that most 
small-to-medium sized compounds are thought to be at least partly metabolized in the 
kidneys. In fact, a majority of polypeptides smaller than 80 kDa circulate in elevated 
concentrations in these patients and appear to rise contemporaneously with a drop in 
glomerular filtration rate (GFR).  Thus, elevated levels of many biomarkers may reflect not 
only increased production as in other patient populations, but also a prolonged half-life due 
to impaired clearance in the proximal tubules. 
In Study 1, we analyzed the mortality risk associated with an elevated level of plasma 
pentosidine in 746 patients with CKD stages 1 - 5 including patients undergoing hemodialysis 
and peritoneal dialysis treatments. Our main finding is that pentosidine is markedly elevated 
in CKD and associates with low GFR, oxidative stress and inflammation, but it remains a 
statistical predictor of mortality in CKD patients also after correction for these confounders. 
In Study 2, we investigated biomarkers in 543 CKD stage 5 patients initiating dialysis 
treatment in terms of their ability to classify patients with clinically overt cardiovascular 
disease (CVD) at baseline and predict all-cause mortality during follow-up for median 28 
months. Following adjustments for confounders such as renal function, none of investigated 
biomarkers were better than simple demographics in predicting adverse outcomes. 
In Study 3, we again assessed the usefulness of biomarkers, now in 224 prevalent 
hemodialysis patients. We assessed their ability to classify presence of clinically overt CVD at 
baseline, as well as predict CVD-related and all-cause mortality during a median 41 months 
follow-up. We found that while circulating pro-brain natriuretic peptides and insulin-like 
growth factor 1 predicted baseline CVD, interleukin 6 predicted CVD-related mortality during 
follow-up, while all-cause mortality was predicted by levels of 8-hydroxy-2’-deoxyguanosine. 
Thus, no biomarker was useful for all three outcomes, and none of the 13 was statistically 
better than demographic data in determining baseline CVD or mortality risks in these 
patients.  
In Study 4, renal biopsies from 15 patients with glomerulonephritis and three biopsies from 
healthy living donors were analyzed for expression of the proximal tubular endocytotic 
proteins megalin and cubilin. Using both immuno-electron microscopy and standard 
immunohistochemistry, we show that megalin and cubilin are not just two components of a 
receptor-endocytosis complex, but rather appear to play distinct roles during albuminuria, as 
evidenced by their differing expression levels. To gain further understanding, we generated a 
proteinuric zebrafish model and showed that megalin and cubilin indeed are influenced by 
tubular albumin levels.  
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Chapter 1  Introduction 
1.1 The kidney 
1.1.1 Kidney anatomy and function 
The kidneys are retroperitoneal structures located under the dorsal ribs, at the thoracic 12 
to lumbar 3 vertebral level, and approximately with the size of a human fist. The left kidney 
is typically somewhat higher than the right on account of the liver. Structurally, each kidney 
is composed of an outer cortex and an inner medulla, each containing parts of the functional 
unit of the filtration apparatus, called a nephron and consisting of a glomerulus and paired 
tubular system. A healthy human is thought to possess approximately 1 million glomeruli in 
each kidney. 
The kidneys can be described as one of the metabolic centers of the body. It filters water 
soluble compounds from the blood thus removing both endogenous and exogenous toxins, 
excess salts and waste products, while also balancing total body water and pH. This occurs 
through a two-step process, passive filtration over the glomerular filtration barrier followed 
by reabsorption and secretion along the tubuli. The filtration product, the primary urine, is 
approximately free from proteins (e.g. albumin) and blood cells as they are too large to pass 
the glomerular filter, but otherwise similar in composition to the systemic circulation, and 
measuring about 180 liters/day. Along the tubules, most of this liquid is reabsorbed along 
with the recycling of many compounds, meaning that the final daily urine output usually is 
about 1 - 2 liters/day. The kidney needs a continuous blood supply to enter the glomerulus 
in order to maintain the filtration pressure, and it is also an important organ in regulating 
blood pressure. 
1.1.2 Glomerular filter 
The glomerulus of the kidney is a highly developed microvascular bed that acts as a filter. It 
is composed of three different cell types, the endothelial cells closest to the vascular space, 
the epithelial cells (podocyte) that is integrated to the glomerular basement membrane 
(GBM) and the mesangial cells holding the capillaries together [1] (Figure 1). The barrier 
allows small molecules, such as water, sugars, electrolytes and small proteins, to pass 
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through while retaining very large macromolecules [2]. It is build up by the endothelial cells 
lining the capillary space and normally has small gaps, fenestration, allowing passage of fluid 
into the GBM. The GBM is built up by collagen fibers and negatively charged macro 
molecules. Podocytes line the outside of the glomerular capillaries and thus face the primary 
urine collected in the space called Bowman’s capsule. The podocytes wrap around the 
adjacent capillaries with foot processes, that in turn interdigitate to form filtration slits. The 
slit pore size was originally reported to be 35 Å with some variation in size [3]. These 
structures are often involved in nephrotic diseases [4, 5]. For example, in minimal change 
nephrotic syndrome (MCNS, Figure 1c), the slit diaphragms loose surface area due to foot 
process effacement [6].  
 
Figure 1. Electron microscopy images of the glomerular filtration barrier with normal structure (1a and 1b) and 
effacement (1c). C=capillary, E=endothelium, FP=foot process, GBM=glomerular basement membrane, 
M=mesangial. 
1.1.3 Proximal tubules 
The proximal tubule begins abruptly at the urinary pole of the glomerulus and comprises an 
initial convoluted portion, the pars convoluta, which is a direct continuation of the parietal 
epithelium of Bowman’s capsule, followed by a straight portion, the pars recta, which is 
located in the medullar border. Finally, the distal convoluted tubules and collecting duct pass 
through the medulla to reach the renal calyx. The proximal convoluted tubule plays a major 
role in the reabsorption of small peptides, Na+, HCO3
-, CI-, K+, Ca2+, PO4
3-, water, and organic 
solutes such as vitamins, glucose, and amino acids. Indeed, approximately 70% of the 
ultrafiltration from renal glomeruli is removed already in the proximal tubules [7].  
 
1a 1b 1c 
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1.1.4 Renal peptide metabolism 
For peptides, recycling in the proximal tubules is thought to be mainly mediated by the two 
receptors megalin (also known as low density lipoprotein-related protein 2, Lrp2) and cubilin 
[8, 9]. They mediate endocytic uptake into clathrin-coated pits, after which the proteins are 
transferred through endosomes to lysosomes for degradation. The receptors are thought to 
return to the apical cell membrane rather than undergoing lysosomal proteolysis [10]. This 
reabsorptive process is extremely efficient as evidenced by the virtual protein-free urine in 
humans. Indeed the most abundant protein in human urine, Tamm-Horsfall protein, is 
secreted further along the tubules [11]. The process of peptide recycling serves not only to 
remove bioactive and osmogenic proteins from the tubule, but also conserves a variety of 
essential substances inside (e.g. amino acids) and attached to (e.g. vitamins) the plasma 
proteins [12].  
The role of megalin and cubilin in this process was recently reviewed in detail by Christensen 
[13]. Briefly, it is thought that megalin serves as a receptor for numerous ligands including 
low-molecular-weight proteins [12], polypeptide hormones [14], albumin [15], vitamin-
binding proteins [16] and polybasic drugs such as aminoglycosides [17]. Cubilin is thought to 
co-localize with megalin in order to anchor to the membrane, but to have several ligands 
that appear to partly overlap those reported for megalin, including albumin and various 
vitamin-binding proteins [12]. A ligand of particular interest is albumin, the most abundant 
serum protein and an important part of proteinuric urine. Albumin has been reported to 
bind to both receptors [15, 18], or essentially to cubilin [19].  
1.1.5 Proteinuria 
Urinary protein excretion up to 150 mg per day may be normal; however, the limits used to 
define presence of albuminuria are usually set at values below 30 mg. A decreasing GFR may 
be associated with an increase in the albumin-to-creatinine ratio and overt albuminuria in 
the general population [20]. When the urinary protein concentration exceeds 3.5 g protein 
per 24 hours, a patient is diagnosed as having nephrotic proteinuria [21]. Physiologically, two 
mechanisms must operate in order to get proteinuria including dysfunction of the selective 
permeability of the glomerular filtration barrier [22, 23] and saturation of proximal tubular 
reabsorption capacity [24]. The hypothetical negative influence of increased tubular 
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endocytosis in glomerular diseases is not fully clear yet [25-28]. However, it is clear that 
proteinuria is either a marker or mediator of harm to the kidney [29] which in the long term 
appears to lead to renal fibrosis, kidney failure and to have implications for systemic vascular 
function.  
1.1.6 Glomerular filtration rate 
The GFR is defined as the volume of fluid filtered from the kidney glomerular capillaries into 
the Bowman’s capsule per unit of time. An exact measurement of GFR is very difficult to 
achieve; instead, minimally invasive and relatively reliable methods are used to estimate GFR 
in the clinical setting.  
In the clinic, even faster and less impractical methods are used based on demographic 
parameters along with a blood sample to determine creatinine that provide estimated GFR 
(eGFR) through various equations. Recent publications have suggested using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [30].  
 
1.2 Chronic kidney disease 
1.2.1 Classification  
The strong correlation of phenotype with GFR has led to a system classifying CKD into 5 
stages, regardless of etiology, shown in Table 1 [31].  
According to the Kidney Disease Quality Outcome Initiative (K/DOQI), CKD is defined as 
abnormalities of kidney structure or function, present for 3 months or more, with 
implications for health [32]. GFR < 60 ml/min/1.73m2 is referred as decreased GFR and GFR < 
15 ml/min/1.73m2 is referred as end-stage kidney failure. Once CKD becomes manifest, we 
currently do not have therapy to reverse it but only to retard progression. Also, the CKD 
phenotype is solely dependent on residual renal function, and thus is very little altered by 
the primary cause of kidney damage. CKD is associated with adverse outcomes, especially 
premature CVD and death [33]. Even in the early stages, CKD confers a risk of fatal and non-
fatal cardiovascular events far exceeding that which occurs in the general population of the 
same age [34].  
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Table 1. Stages of chronic kidney disease. 
Stages GFR (ml/min/1.73m2) Description 
Stage 1 > 90 Structural damage with normal or high GFR 
Stage 2 60 - 89 Structural damage with mildly decreased GFR 
Stage 3a 45 - 59 Mildly to moderately decreased GFR 
Stage 3b 30 - 44 Moderately to severely decreased GFR 
Stage 4 15 - 29 Severely decreased GFR 
Stage 5 < 15 Kidney failure and requiring renal replacement therapy 
 
1.2.2 Epidemiology of CKD 
According to the 2015 annual report by the United States Renal Data Systems (USRDS), the 
overall prevalence of CKD in the U.S. increased from 12% in 1988 - 1994 to 14% 2007 - 2012, 
and 117 162 patients were living with ESRD in 2013. These had adjusted annual mortality 
rates of 14%, 17% and 4% for ESRD, dialysis and transplant patients, respectively [35]. While 
a recent large-scale in Europe that attempted to carefully characterize CKD prevalence 
identified substantial variation in CKD prevalence between countries, these differences 
appear to be caused by factors other than the prevalence of diabetes, hypertension and 
obesity [36]. 
In the Stockholm region it is estimated that 6% of adult individuals have CKD insert 2006 - 
2011 [37]. In Sweden, there were 11 373 known CKD patients in 2014, most of whom (94%) 
had CKD stage 3 - 5 [38].   
1.2.3 Effects of declining renal function 
As may be expected, the many roles of the kidney in human physiology mean that a decline 
in function impacts normal body function in multiple ways. First, metabolic acidosis is 
normally counteracted by renal excretion of hydrogen ions. With a loss of renal function 
acidosis invariable appears [39]. Furthermore, renal generation of bicarbonate is also 
impaired when the damage progresses, worsening the metabolic acidosis [39].  
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High potassium level represents another major pathophysiological consequence of declining 
GFR. Potassium is to 90% excreted by the kidney [40], explaining why even a modest decline 
in renal function leads to hyperkalemia.  Depending on the severity, hyperkalemia may result 
in neurological and heart rhythm problems. 
Likewise, imbalances of calcium and phosphate linked to reduced excretion by the kidney as 
well as reduced production of active vitamin D results in a number of clinical complications 
[41]. Perhaps most noticeably, renal patient suffer osteoporosis and enhanced vascular 
calcification [42]. 
Uremic toxicity occurs in the later stages of CKD, and result from the failure of the kidneys to 
remove potentially toxic compounds from the blood stream, causing their accumulation in 
the body [43]. The exact toxicity of individual compounds as well as their effects on the body 
remain poorly characterized [44]. 
Hypertension is present in more than 80% of patients with CKD [45], constituting both a  
cause and a consequence of the progression of CKD and cardiovascular damage [46]. 
Furthermore, hypertension is often associated with proteinuria, which is the common 
phenotype of kidney disease. Proteinuria is considered both a marker of progression in renal 
disease [29] and a driver of cardiovascular events [47].  
In a normal adult, approximately 3.5 - 4.5 g protein/kg body weight are synthesized and 
degraded each day with the majority being intracellular proteins [48]. In CKD, this amount 
may be reduced as evidenced both by signs of increased muscle catabolism but also by low 
circulating concentrations of high-abundance proteins such as albumin. 
Muscle wasting itself is another major complication of CKD and is reported to be progressive 
[49]. The mechanism are incompletely understood, but involve impaired insulin/IGF-1 
intracellular signaling, which stimulates protein degradation through altered ubiquitination 
[50].  
1.2.4 Renal replacement therapy (RRT) 
Patients with ESRD require RRT with either kidney transplantation or dialysis, in many cases 
both over a lifetime. The two main methods of conducting dialysis, hemodialysis (HD) and 
peritoneal dialysis (PD), have approximately similar outcomes but their application varies 
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between countries for both medical and logistic reasons. In Sweden where approximately 79% 
of dialysis patients are on HD and 21% on PD, the annual mortality rate in the dialysis 
population was 20% and for transplant patients is 2% [38].  
Dialysis today entails the removal only of water and solutes. This leaves larger molecules 
such as proteins in place, with unknown consequences. Also the loss of residual renal 
function with time, a process that occurs also in patients on dialysis, has been found to 
contribute to poor clinical outcomes [51, 52]. Dialysis itself is associated with 
hypermetabolism and inflammation [53], while central dialysis catheters are a major cause 
of inflammation and infections leading to premature deaths [54]. Thus, it is not surprising 
that the survival of dialysis patients is relatively poor.  
Transplantation of a kidney from a living or deceased donor constitutes the second form of 
RRT, and is associated with improved survival and quality of life as compared to other 
options. However, the renal allograft is constantly at risk of rejection and 
immunosuppressive therapy must therefore be maintained. 
 
1.3 Mortality risk factors and their biomarkers 
A risk factor is a variable that has association with a certain disease or disease process in an 
individual or a population. It is used for identifying subjects at increased risk of an adverse 
outcome. When it comes to CVD, the Framingham study has led the way in linking factors 
such as old age, smoking, hypertension, dyslipidemia, diabetes to CVD and increased 
mortality. However, in CKD patients the impact of these common risk factors is muted, 
despite a very high prevalence of left ventricular hypertrophy and hearth failure. Instead a 
number of novel risk factors have been proposed. These include protein energy wasting 
(PEW), circulating inflammatory cytokines, endothelial dysfunction, fluid overload and 
vascular calcification [55, 56]. However, while all of the above are associated with an adverse 
outcome, there is to date no single test or marker that may be used to predict which 
patients will do well and which will suffer CVD.  
In this context, a number of circulating biomarkers have been proposed as risk markers in 
renal disease patients [57]. Most are only validated in small cohort studies and the impact of 
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residual renal function on them is not well established. Furthermore, except for the markers 
of GFR, quantitative indicators of pathologic processes that vary continuously with the 
progression of disease, including glomerular membrane leakage,  sclerotic glomeruli and the 
amount of interstitial fibrosis are lacking [58].  
Below, a number of common complications of CKD associated with adverse outcomes (in 
particular premature death) are discussed along with biomarkers that have been proposed. 
1.3.1 Protein-energy wasting (PEW) 
PEW is a relatively new term for describing the progressive depletion of protein and/or 
energy stores that occurs in patients with CKD [59], and is associated with adverse clinical 
outcomes [60]. According to a proposal by the International Society of Renal Nutrition and 
Metabolism (ISRNM), the optimal diagnosing of PEW is based on the presence of 
biochemical criteria, together with a reduced body mass and a reduced muscle mass [61].  
The reported prevalence of PEW in maintenance HD and PD patients ranges from 18% to 75% 
[62, 63]. While PEW is a prognostic factor associated with mortality [64], to date no accurate 
biomarker exists to reflect PEW while interventions available to treat it are often ineffective.  
Studies suggest that PEW is accompanied by increased inflammation [65], resistance of 
skeletal muscle to insulin [66] and muscle atrophy [67], as well as reduced serum albumin 
concentrations [68, 69]. As mentioned, few interventions are successful and novel treatment 
strategies are needed [64]. 
Several biomarkers have been proposed to reflect PEW, but none is accepted in clinical 
practice. The markers range from the traditionally used serum albumin [69], cholesterol [70], 
creatinine [71] and IGF-1 [72], to newer markers such as IGF binding protein (BP)-1 [73] and 
myostatin [74].  
1.3.2 Cardiovascular disease 
CVD is the major cause of death in patients with CKD, and even a mildly reduced renal 
function results in a dramatically increased risk of premature CVD and death [75, 76]. The 
cardiovascular risk in CKD cannot solely be explained by traditional risk factors such as 
hypertension, dyslipidemia, smoking, DM or obesity [77]. The uremic phenotype itself entails 
a wide variety of metabolic disturbances known to increase cardiovascular risk such as 
9 
 
oxidative stress and inflammation [78], endothelial dysfunction [79] and vascular 
calcification [80]. Arteriosclerosis due to both intimal disease and medial calcification is a 
common finding in CKD and affects both small and large arteries [81].  
Another pathway implicated in uremic CVD is the B-type natriuretic peptides (BNP) pathway. 
BNP belongs to a system of natriuretic peptide that has a major role in regulating blood 
pressure and volume through direct effects on the kidney and systemic vasculature [82, 83]. 
BNP is synthesized as an amino acid precursor protein by the heart, and then undergoes 
intracellular modification to a more stable N-terminal cleavage product (NT-proBNP). 
Prevalence of elevated BNP or NT-pro-BNP levels is high in patients with CKD [84] and has 
been linked to CVD and death [85].  
Troponin T (TnT) is another biomarker implicated in CKD-CVD. It is one of the components of 
the contractile apparatus of striated muscle, and is mainly present in the heart [86]. TnT is 
detected in high concentrations in serum from patients with ESRD [87] in whom it predicts 
CVD [88]. 
1.3.3 Vascular ossification 
Cardiovascular ossification of the intima and especially the media is common in CKD patients 
[89], while the proteins fetuin-A and osteoprotegerin (OPG; both mediating calcium 
homeostasis) are related to arterial stiffness and atherosclerosis in this group [90]. In medial 
calcification a differentiation from smooth muscle cells to osteoblast-like cells takes place 
[91] giving a bonelike matrix production and mineralization that happens in the presence of 
high calcium and phosphorus [92]. Vascular calcification and inflammation are interrelated in 
CKD, perhaps in part mediated via phosphate retention and/or bone disease [93]. Fetuin-A is 
often decreased in the inflamed uremic milieu and has a positive relation to survival in HD 
and PD patients [94], while OPG associates with progression of coronary artery calcification 
and mortality and is increased in HD patients with CVD [95].  
1.3.4 Proteinuria 
Proteinuria plays an important role in the pathogenesis of CKD progression [96, 97]. 
Epidemiological studies have demonstrated a graded relationship between increased 
proteinuria and mortality as well as kidney outcomes in diverse study populations [98]. This 
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association appears to be independent of low GFR and the role of proteinuria as a risk factor 
for CVD is well established [99]. 
The exact mechanisms that link proteinuria to kidney disease progression remain unclear 
[100]. Clearly albumin leakage into the final urine is pathological, and may reflect a 
combination of filter damage and reduced compensatory capacity of the proximal tubule 
endocytotic apparatus [101]. The damage is likely then propagated by the toxic effects of 
proteins (including albumin overload) on the proximal tubule epithelium, causing interstitial 
inflammation and fibrosis [102].  
1.3.5 Oxidative stress 
Oxidative stress - loosely defined as an excess of oxidative compounds and insufficient 
antioxidant defense mechanisms [103] appears to increase as CKD progresses and may 
correlate inversely with renal function [104, 105]. In CKD, more stable forms of oxidative 
damage such as advanced glycation end products (AGEs) accumulate [106]. Retention of 
AGEs and other pro-oxidants is likely to contribute to a pro-inflammatory milieu as renal 
function declines [107]. The specific interaction between AGEs and their receptors further 
specifically contributes to generation of intracellular oxidative stress [108]. Likewise, 
pentosidine (mainly in the form of a combined AGE-protein complex [109]) is remarkably 
increased in dialysis patients and predicts CVD and disorders of bone mineralization [110]. 
Another biomarker 8-hydroxy-2’-deoxyguanosine (8-OH-dG) is one of the most abundant 
oxidative products of nucleic acids [111]. The circulating level of 8-OH-dG is elevated in 
patients with CVD  and predict all-cause mortality in dialysis patients [112]. 
1.3.6 Inflammation 
The phenotype of CKD is often accompanied by systemic inflammation, which may promote 
progression [113], premature ageing [76] and CVD [114]. In the general population, 
persistent inflammation is related to poor clinical outcomes, mainly cardiovascular disease 
[114], and the same risk is found in CKD patients, especially after the start of dialysis [115].  
The causes of inflammation in CKD are not known. One hypothesis is that retention of 
circulating cytokines [116], AGEs [107], and/or other pro-oxidants [104] contribute to a pro-
inflammatory milieu as renal function declines. The chronic low-grade inflammation 
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engendered may play a central role for the uremic phenotype, as evidenced by the high 
prevalence of micro inflammation [117]. Various clinical events are also common causes of 
inflammation in CKD [118]. 
Reviewing the literature, Kalantar-Zadeh has reported more than 40 inflammatory markers 
which have been studied in patients with CKD [119]. In this thesis, pentraxins, several pro-
inflammatory cytokines and adhesion molecules will be discussed. Amongst them, CRP is an 
acute phase reactant produced in the liver that already in the 1990s was shown to be a 
powerful predictor of CVD related death and all-cause mortality in HD [120] and PD patients 
[121]. Today, CRP is widely used in as a marker of inflammation in the clinic due to its low 
cost, high reliability, and extensive availability for detection [122]. Pentraxin 3 (PTX3), which 
belongs to the pentraxin family of proteins that also includes CRP, is an acute phase reactant 
involved in pathogen recognition, complement activation and regulation [123]. PTX3 is 
elevated in dialysis patients compared to healthy controls and reflects endothelial 
dysfunction [124]. It is associated with cardiovascular disease and mortality risk [125].  
IL-6 is a cytokine produced by various cells including T-cells, mast cells, macrophages, and 
endothelial cells [126]. It is also well-known to be a strong predictor of mortality in incident 
and prevalent HD patients [127]. Another pro-inflammatory cytokine TNF-α has a pivotal role 
in regulating both pro- and anti-inflammatory mediators [128]. Elevation of TNF-α also 
predicts clinical outcomes in dialysis patients [116], even after controlling for age and serum 
albumin level [57].  
Finally, adhesion molecules including intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) are found on endothelial cells [129]. Several are 
known to be elevated in patients on dialysis [130]. As the formation of atherosclerosis is 
partly caused by the adhesion of leukocytes to the vascular endothelium following various 
pro-inflammatory signals [131] they also represent a possible biomarker for CVD in the 
setting of uremia. 
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Chapter 2  Aims 
The overall aim of this thesis is to investigate the impact of impaired renal function (possible 
related to proximal tubular endocytosis) on the usefulness of selected biomarkers of 
outcomes in patients with CKD. 
Specifically, we had the following objectives: 
Study 1: To investigate the statistical performance of a single measurement of the plasma 
concentration of pentosidine - in relation to plasma albumin to which pentosidine is bound - 
as a predictor of mortality risk in CKD patients. 
Study 2: To evaluate the usefulness of several common peptide and nucleotide biomarkers 
as predictors of clinical outcomes in ESRD patients.  
Study 3: To evaluate a similar panel of biomarkers in prevalent HD patients. 
Study 4: To investigate expression patterns of megalin and cubilin in proximal tubules from 
patients with different glomerulopathies and varying grades of albuminuria. 
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Chapter 3  Materials and Methods 
3.1 Ethical considerations 
All studies in this thesis adhere to the Declaration of Helsinki for human studies. The Ethics 
Committee of the Karolinska Institute at the Karolinska University Hospital Huddinge, 
Stockholm, Sweden, approved the study protocol of the Prima control, Prima, MIA, MIMICK 
1, MIMICK 2 and LD-Rtx cohort studies, as well as the use of healthy individuals and renal 
biopsies. Informed consent was obtained from each patient and healthy individuals. The 
study of zebrafish embryos was performed by Zebrafish Core Facility, Karolinska Institute.  
 
3.2 Study protocols 
3.2.1 Study 1 
The study is based on post hoc analysis of baseline data and subsequent longitudinal follow-
up of 746 participants from the six cohorts - the Prima control, Prima, MIA, MIMICK 1, 
MIMICK 2 and LD-Rtx - with varying degrees of renal failure as follows: 37 individuals in CKD 
stage 1 - 2, 54 in CKD stage 3 - 4, 386 in CKD stage 5 but were investigated prior to starting 
on dialysis (CKD 5 - ND), 195 were prevalent HD patients and 74 were prevalent PD patients. 
Plasma pentosidine, biomarkers of inflammation, oxidative stress and nutritional status were 
investigated, and mortality data collected. 
3.2.1.1 CKD stage 1 - 2  
The Prima control cohort represents a population based sample with signs of mild CKD 
(micro- or macro- albuminuria or reduced GFR) and served as control group for the Prima 
study cohort. The Prima control cohort comprised 37 individuals from the Stockholm region, 
randomly selected by Statistics Sweden (a government agency) and accepting to participate. 
Recruitment was carried out by mail between February 2003 and April 2004. More detailed 
description of the study has previously been published [132]. The median age was 68 years, 
median eGFR was 79 ml/min/1.73m2 and the prevalence of CVD was 8%, while 6% of 
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participants were classified as malnourished (SGA >1). Over a median 60 months of follow-
up, 2 individuals died.  
3.2.1.2 CKD stage 3 - 4  
The Prima cohort consists of 54 CKD stage 3 - 4 patients recruited from December 2001 until 
March 2004. The description of the study has previously been published [132]. In brief, 
patients being seen at the outpatient clinic of the Karolinska University Hospital were asked 
to enroll after informed consent. The median age was 60 years, 74% were males, median 
eGFR CKD-EPI was 27 ml/min/1.73m2, 21% were malnourished, 44% had diabetes and 26% 
had CVD. The most common causes of CKD were diabetic nephropathy (25%) and 
glomerulonephritis (23%). Over a median 60 months of follow-up, 24% of patients died. 
3.2.1.3 CKD 5 - ND 
MIA (Malnutrition, Inflammation and Atherosclerosis in CKD) is a cohort coordinated by the 
Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, 
Karolinska Institutet that recruits incident patients starting renal replacement therapy. This 
ongoing cohort study is described in detail elsewhere [65]. 
There are 386 incident dialysis patients were recruited (from June 1994 through October 
2012). The median age was 55 years, 60% were male, median eGFR CKD-EPI was 6 
ml/min/1.73m2, 30% were malnourished, 31% had CVD and 28% had DM. The causes of CKD 
were chronic glomerulonephritis (23%) and diabetic nephropathy (25%). The majority of 
patients were on antihypertensive medications; 59% of patients were prescribed a beta (β) -
blocker, 54% angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 
(ACEi/A2RB), 45% calcium channel blocker and 21% received statin treatment. The majority 
of patients were on antihypertensive medications and other commonly used drugs in CKD, 
such as phosphate and potassium binders, diuretics, iron substitution and vitamin B, C, and 
D supplementation. During 32 months follow up, 27% of patients died. 
3.2.1.4 Prevalent HD 
A total of 195 prevalent HD patients were included in the MIMICK 1 (Mapping of 
Inflammation Markers in Chronic Kidney Disease 1) cohort, which was recruited from 
October 2003 until September 2004. A description of the study was presented previously 
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[133]. The median age was 64 years, 57% were males, 23% had diabetes, 61% had CVD, 45% 
were malnourished (SGA >1) while most of the patients in this cohort were functionally 
anuric with no or minimal residual renal function. The most common causes of CKD were 
glomerulonephritis (20%), diabetic nephropathy (18%) and hypertension/renal vascular 
disease (13%). Most patients were on anti-hypertensive medications such as β-blockers 
(48%), calcium channel blockers (27%), ACEi/A2RB (34%) while some were taking statins 
(32%). Most also received medications common to CKD stage 5 with dialysis, such as 
phosphate and potassium binders, diuretics, and vitamin B, C, and D supplementation. 
During a median follow-up of 41 months 48% died. 
3.2.1.5 Prevalent PD 
A total of 74 prevalent PD patients were recruited from March 2008 to March 2011 to take 
part in the MIMICK2 (Mapping of Inflammation Markers in Chronic Kidney Disease 2). A 
description of the study has previously been published [112]. In summary, the median age 
was 61 years, 64% were males and median eGFR CKD-EPI was 6 ml/min/1.73m2. Further 20 % 
had diabetes, 22 % had CVD, and 42% were malnourished (SGA score >1). CAPD was used by 
75% of patients and the remaining 25% patients were treated by automated peritoneal 
dialysis (APD). The most common causes of CKD were glomerulonephritis (13%), diabetic 
nephropathy (12%) and hypertension/renal vascular disease cause (12%). Most patients 
were on anti-hypertensive medication β-blockers (68%), calcium channel blockers (31%), 
ACEi/A2RB (69%). Most patients received medication such as phosphate and potassium 
binders, diuretics, and vitamin B, C, and D supplementation. After a median follow up 25 
months, 38% of patients had died. 
3.2.1.6 LD-Rtx 
In Study 1, 59 CKD patients are from LD-Rtx (undergoing living donor kidney transplantation) 
cohort, which was recruited at the Department of Transplantation Surgery of the Karolinska 
University Hospital between May 2009 and October 2013. More details about this ongoing 
cohort have been published previously [134]. There are 24 patients allocated to CKD stage 5 
- ND, 17 to prevalent HD and 18 to prevalent PD.  
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3.2.2 Study 2 
In Study 2, 543 incident dialysis patients from the MIA cohort (from June 1994 through 
November 2014) were included. The median age was 56 years, 63% were male, median 
eGFR CKD-EPI was 9.5 ml/min/1.73m2, 33% were malnourished, 37% had CVD and 31% had 
DM. The causes of CKD were chronic glomerulonephritis in 126 patients (23%), diabetic 
nephropathy in 159 patients (29%; of which 125 were treated with insulin), 
hypertension/renal vascular disease in 113 patients (21%) and other or unknown etiologies 
in 145 patients (27%). The majority of patients were on antihypertensive medications; 63% 
of patients were prescribed β-blocker, 60% ACEi/A2RB, 49% calcium channel blocker and 27% 
received statin treatment. During median follow up 28 months follow up, 28% of patients 
died. 
The final selection of biomarkers to be included was based on the availability of previous 
measurements and their clinical utility (commercial kits available for analysis and reported to 
predict either CVD or mortality in the CKD 5 population).  
3.2.3 Study 3 
The Study 3 was comprised 224 prevalent hemodialysis patients from MIMICK 1 (from 
August 2003 until September 2004). The median age was 66 years, 55% were males, 26% 
had diabetes, 63% had CVD, 47% were malnourished (SGA >1) while most of the patients in 
this cohort were functionally anuric with no or minimal residual renal function. The most 
common causes of CKD were glomerulonephritis (17%), diabetic nephropathy (18%) and 
hypertension/renal vascular disease (17%). Most patients were on anti-hypertensive 
medications such as β-blockers (50%), calcium channel blockers (25%), ACEi/A2RB (34%) 
while 32% were taking statins. During a median follow-up of 41 months 53% died. 
The Study 3 uses similar criteria as in Study 2 to select biomarkers that were studied as 
predictors of CVD, CVD-related mortality and all-cause mortality.  
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3.2.4 Study 4 
3.2.4.1 Human biopsies 
Briefly, using patient records we identified 15 patients (median age 29 years, 10 males) 
diagnosed with specific kidney diseases by diagnostic renal biopsy at the Karolinska 
University Hospital between 2000 and 2013. There were nine biopsies from patients with IgA 
nephropathy (IgAN) presenting different degrees of albuminuria, three biopsies from 
patients with minimal changes nephritic syndrome (MCNS) and three biopsies from patients 
with thin membrane disease (TMD). Biopsies from three healthy living kidney donors were 
used as controls. Biopsies were performed under ultrasound guidance and using standard 
equipment. Control kidney biopsies were taken immediately after removal of the donor 
kidney and before flushing with the preservative solution. 
For light microscopy, the specimens were fixed in 4% phosphate buffered formalin, then 
dehydrated and embedded in paraffin according to standard procedures. Sections of 1.5 µm 
were cut on a microtome and stained with hematoxylin and eosin, periodic-acid Schiff, 
Ladewig’s trichrome, and periodic acid silver.  Materials for diagnostic transmission electron 
microscopy were fixed in a mix of 2.5% glutaraldehyde and 0.5% paraformaldehyde and 
embedded in an epoxy resin. The blocks were cut into approximately 60 nm thick sections 
and evaluated in a transmission electron microscope (TEM). A small piece of each kidney 
biopsy was also collected for immuno-electron microscope (iEM). The tissue was fixed in a 
solution containing 0.1M phosphate-buffered 1% paraformaldehyde and 0.5% 
glutaraldehyde and processed for low temperature embedding into K11M [135]. 
The histopathology of the included patients’ biopsies was re-examined by an experienced 
renal pathologist to confirm the previously reported diagnoses. Tubular atrophy and 
interstitial fibrosis were semi-quantified according to Banff criteria [136]. Thus, tubular 
atrophy was graded between 0 - 3; 0 = none, 1 = affecting 0 - 25%, 2 = affecting 26 - 50%, 
and 3 = affecting >50% of the cortical area. Interstitial fibrosis was graded 0 - 3; 0 = affecting 
0 - 5%, 1 = affecting 6 - 25%, 2 = affecting 26 - 50%, and 3 = affecting >50% of the cortical 
area.  
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3.2.4.2 Zebrafish biopsy 
A proteinuric zebrafish model was generated by morpholino-mediated knock-down of nphs2 
as described earlier [137]. The morpholino antisense oligo (MO) targeting nphs2 (5’-TAGACT 
TACCTTCTCCAGGTCCCTC) and a standard control MO (5’-CCTCTTACCTCAGTTACAATTTATA) 
were obtained from GENE TOOLS, LLC (Philomath, OR, USA). Two doses (50 µM and 100 µM) 
of nphs2 MO were injected into one- or two-cell embryos, respectively. As a control, 100 µM 
of control MO was similarly injected. We used embryos from a wild-type AB zebrafish line, 
which is maintained and raised in the Zebrafish Core Facility, Karolinska Institutet, as 
previously described [138].  
Whole zebrafish embryos were observed using a Leica MZ12 dissecting stereomicroscope 
with an attached digital camera. Pericardial edema of the morphants was analyzed and 
photographed at 4 days post fertilization (dpf). For TEM and iEM, 4-dpf morphants were 
fixed with 3% PFA and kept at 4C until the next procedure for dehydration and embedding. 
Materials for diagnostic transmission electron microscopy were fixed in a mix of 2.5% 
glutaraldehyde and 0.5% paraformaldehyde and embedded in an epoxy resin. The blocks 
were cut into approximately 60 nm thick sections and evaluated in TEM. 
We classified the biopsied patients according to their diagnosis and albuminuria: Group 1 
comprised IgAN with microalbuminuria (IgANL, albuminuria >30 mg/24h and <300 mg/24h, 
n=3) [139, 140] along with TMD (no albuminuria); Group 2 comprised IgAN with macro 
albuminuria (IgANM, albuminuria >300 mg/24h but <3500 mg/24h, n=3) [140]; and Group 3 
with IgAN with nephrotic degree of albuminuria (IgANH, albuminuria >3500 mg/24h, n=3) 
along with MCNS (albuminuria >3500 mg/24h, n=3). The expression of megalin and cubilin in 
proximal tubular sections was investigated by iEM and IHC, while a similar study was 
performed in proteinuric zebrafish as supplementary confirmation or comparison.  
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3.3 Methods 
3.3.1 Anthropometric and metabolic evaluation 
Height and body weight were obtained at baseline and BMI was recorded. SGA was used to 
evaluate overall PEW as previously described [49]. PEW was defined as SGA score >1. HGS 
was measured using a Harpenden Handgrip Dynamometer (Yamar, Jackson, MI, USA) in the 
dominant hand. The individual values for HGS were expressed as % of healthy subjects, 
adjusting for the gender.   
Arterial systolic and diastolic blood pressures (BP) were measured three times in the 
morning after a 15 min resting period, and the mean pressure used. In non-diabetic patients, 
insulin resistance was calculated by the homeostasis model assessment for insulin resistance 
[141]. Insulin resistance was not assessed in diabetic subjects. 
3.3.2 Biochemical Analysis  
Blood samples were collected at baseline evaluation. The plasma was separated within 30 
minutes, and samples were kept frozen at –70° C if not analyzed immediately.  
Concentrations of hemoglobin and serum albumin (intra-assay CV: 3 - 4%) (bromcresol 
purple), creatinine, ferritin (intra-assay CV: 6%), hemoglobin A1c (HbA1c%), hsCRP (intra-
assay CV: 5%; inter-assay CV: 6%) (nephelometry), orosomucoid (intra-assay CV: 5 - 7%), PLT 
(intra-assay CV: 5 - 7%), TnT (intra-assay CV: 8%), urea, WBC (intra-assay CV: 6%) and plasma 
concentrations of cystatin C and glucose were determined by routine methods at the 
Department of Laboratory Medicine, Karolinska University Hospital. Commercial ELISA kits 
were used to determine sVCAM-1 (intra-assay CV: 3.5%; inter-assay CV: 6%) and sICAM-1 
(intra-assay CV: 4%; inter-assay CV: 5%) (R&D Systems Europe, Ltd, United Kingdom). Plasma 
concentrations of insulin, IGF-1 (intra-assay CV: 4.3%; inter-assay CV: 6.9%), IL-6 (intra-assay 
CV: 4%; inter-assay CV: 5%) and TNF-α (inter-assay CV: 5%) were measured on an Immulite 
TM Automatic Analyzer (Siemens Healthcare, Diagnostics Products Ltd. United Kingdom), 
using assays manufactured for this analyzer and according to the manufacturer’s instructions. 
Plasma pentosidine was analyzed by reverse-phase high performance liquid chromatography 
(HPLC) as described previously [107]. Circulating pentosidine is mainly present in protein 
bound form with albumin [142]; therefore, the total plasma pentosidine concentration 
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measured in nmol/L was corrected for albumin and expressed as nmol of plasma pentosidine 
per gram of albumin. 
3.3.3 Antibodies 
Following light microcopy to determine the integrity and structure of the proximal tubules in 
each biopsy, we studied human samples using iEM employing sheep anti-megalin and rabbit 
anti-cubilin antibodies (gift from Professor Renata Kozyraki, Institute de la Vision, INSERM, 
Paris, France) as well as rabbit anti-albumin antibodies (Sigma, cat. No. A3293-2ML). To 
detect the signal of reabsorbed protein in the larval zebrafish proximal tubules, a sheep anti 
full-length rat albumin antibody (Bethyl Laboratories, Inc; cat. no. A110-134A) was used. For 
immunohistochemistry staining, we used antibodies to megalin (Atlas, cat. no. HPA005980) 
and cubilin (Biorbyt, cat. no. orb4997). The same antibodies were also used for zebrafish iEM 
analysis as a Blast analysis showed that zebrafish homology of the immunogenic peptides for 
megalin and cubilin was 80% and 83% similar to human, respectively. Normal sheep serum 
(Dako, cat. no. X 0503) and normal rabbit IgG (Dako, cat. no. X0903) were used as negative 
controls. To detect bound antibodies, a secondary gold-conjugated protein A (10 nm) or 
gold-conjugated donkey anti-sheep (10 nm) antibody (British Biocell International, cat. no. 
7687 and 15249) were used. 
3.3.4 Immunohistochemistry (IHC) 
IHC was performed on paraffin sections from all biopsies using the standard IHC protocol in 
the Department of Pathology and staining was analyzed by using a Bond-III microscope 
(Leica Biosystem, Germany). Antibodies to megalin (1:500) and cubilin (1:200) were used. 
3.3.5 iEM and semi-quantification of protein expression 
All sections were analyzed in a Tecnai 10 microscope (FEI, Eindhoven, The Netherlands) at 
100 kV and digital images were captured with a Veleta camera (Olympus Soft Imaging 
Solutions GmbH, Münster, Germany).  
To determine the number of images needed for an appropriate sampling, we used a 
cumulative mean plot as previously described [143]. In the present study, ten proximal 
tubules were chosen randomly and in each tubule three different areas were selected. In 
each area one image at a primary magnification of 39 000 × covering brush border and one 
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image covering the adjacent apical cytoplasmic vesicles were taken. Thus, thirty images were 
analyzed in each compartment, respectively. The area of the corresponding compartments 
was calculated by point counting using a 1 x 1 cm square lattice, and expressed as µm2  [143]. 
The number of gold particles was counted in the images and the concentration of each 
protein was calculated by dividing the total number of gold particles by the area, and 
expressed as gold particles/µm2 (Au/µm2). The mean concentration was then calculated in 
each compartment. 
The method described [143] was used to calculate the images of zebrafish samples. Since 
the zebrafish nephron only has two tubules, four consecutive sections were analyzed in each 
zebrafish tubuli, and in each section five areas including brush border and cytoplasm were 
randomly selected. Thus, twenty images were analyzed in each compartment, respectively. 
3.3.6 Statistical analysis 
Data are expressed as median (10th to 90th percentile) or percentage or as appropriate. 
Statistical significance was set at the level of p<0.05. All statistical analyses were performed 
using statistical software GraphPad Prism version 7.0 (GraphPad Software Inc, CA, USA) and 
SAS version 9.4 (SAS Campus Drive, Cary, NC, USA). 
Comparisons between two groups were assessed with the nonparametric Wilcoxon test, 
while for three or more groups Kruskal-Wallis ANOVA test was used, followed by Dunn’s test.  
Fischer exact test or Chi-square test was used for nominal variables. Non-parametric 
Spearman rank correlation analysis was used for continuous and ordinal variables.  
To ensure that the best possible cut-off for each biomarker was used for each biomarker, 
separate receiver operating characteristics (ROC) curves were plotted and areas under the 
curves (AUC) calculated prior to each dichotomous analyses and using the same outcome 
variable. ROC curves were generated by plotting the relationship of the true positivity 
(sensitivity) and the false positivity (1-specificity) at various cutoff points, and AUC was 
defined as the area under the resulting curve. An AUC of 1.0 was defined as perfect 
prediction with no false positives, while an AUC of 0.5 indicated no diagnostic value. 
In Study 1, to study the associations between 1 standard deviation (1-SD) increments of 
pentosidine/albumin we used linear multivariable regression analysis. To ascertain the 
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adjusted RR for death associated with each 1-SD higher pentosidine/albumin, multivariable 
GENMOD regression analysis was performed. A multiple imputation of missing values was 
performed using the function PROC MI, with all variables in the covariate section used to 
produce the values for imputation. ROC curves were analyzed allowing calculation of areas 
under the curves (AUCs) and cut-off values for pentosidine/albumin in relation to all-cause 
and CVD-related deaths. 
In Study 2, adjudication of outcomes included determination of optimal cut-off values for 
each biomarker to be used for dichotomous analysis, followed by multivariable GENMOD 
regression analysis and multinomial logistic regression analysis. The predictive strength, 
expressed as pseudo r, of biomarkers to classify presence of clinically overt cardiovascular 
disease and all-cause mortality risk during follow-up of up to 60 months. 
In Study 3, to study the associations between the presence of clinically overt CVD and other 
20 parameters, a multivariable GENMOD regression analysis was performed. A multiple 
imputation of missing values was performed using the function PROC MIANALYZE, with all 
variables in the covariate section used to produce the values for imputation. The results for 
each imputation were generated using PROC GENMOD, and then combined using PROC 
MIANALYZE. As sensitivity analyses showed minimal effects of imputation, reported results 
are based on an imputed complete-case analysis (n=224). 
In Study 4, comparisons between six groups among patient biopsies and three groups 
among zebrafish biopsies were performed using the general linear models (GLM) test. 
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Chapter 4  Results and discussion 
4.1 Overall summary 
In the present thesis, we investigated the hypothetical role of proximal tubular protein 
metabolism on the predictive value of common and novel circulating biomarkers of CVD risk 
and mortality in patients with different degrees of reduced renal function and albuminuria. 
We found that demographic factors were more sensitive than most protein biomarkers 
when predicting risks in the CKD population. Furthermore, studies suggest that proximal 
tubular protein endocytosis is active also in disease states of micro albuminuria, suggesting 
that it may be also important to assess urinary biomarkers. At present, we do not consider 
any of the investigated biomarkers to give additional information on mortality risk above 
and beyond that obtained from careful clinical assessments and demographic data, 
presumably because none of them directly reflect the pathophysiological pathways that 
mediate CVD in CKD. 
 
4.2 Most protein biomarkers do not perform better than demographics 
In Study 1 - 3, we investigated the ability of multiple biomarkers to predict clinical outcomes 
in various cohorts of CKD patients. We found the predictive power, even optimized by a 
ROC-maximized cut-off, to be relatively low. In fact, most protein biomarkers were no longer 
significant predictors following adjustment for age, gender, diabetic status and nutrition 
status. This was true both in early and late stage CKD, and in classifying baseline CVD, CVD-
related mortality and all-cause mortality.  
In Study 1, 1-SD higher pentosidine/albumin independently predicted all-cause mortality 
(RR=1.04, 95% CI: 1.01 - 1.08, p=0.01) and CVD mortality (RR=1.03, 95% CI: 1.01 - 1.06, 
p=0.03) after adjusting for all confounders in CKD patients with different stages and 
therapies. However, the nutrition, CVD and DM status respectively were each even stronger 
predictors of all-cause mortality and CVD mortality. In Study 2, IL-6 is a classifier of clinically 
overt CVD (RR=1.10, 95% CI: 1.02 - 1.19, p=0.01) and predictor of all-cause mortality 
(RR=1.79, 95% CI: 1.20 - 2.67, p=0.01) after adjusting for all confounders in patients with 
24 
 
stage 5 CKD. However, age (RR=1.31, 95% CI: 1.22 - 1.41, p<0.001), smoking (RR=1.15, 95% 
CI: 1.07 - 1.23, p<0.001), diabetic status (RR=1.24, 95% CI: 1.14 - 1.34, p<0.01) and nutrition 
status (RR=1.10, 95% CI: 1.02 - 1.19, p<0.001) are even better predictors of presence of 
baseline CVD, while nutrition status (RR=2.28, 95% CI: 1.56 - 3.33, p<0.001) is the best 
predictor for all-cause mortality. In Study 3, after adjustment of all confounders, proBNP 
(RR=1.25, 95% CI: 1.10 - 1.42, p<0.001) and IGF-1 (RR=1.14, 95% CI: 1.01 - 1.29, p=0.03) are 
classifier for clinical CVD; IL-6 predicted CVD mortality (RR=2.80, 95% CI: 1.34 - 5.87, p=0.006) 
and 8-OH-dG predicted all-cause mortality (RR=1.56, 95% CI: 1.02 - 2.36, p=0.04). 
Nevertheless, age, smoking and DM are all better predictors of CVD mortality and all-cause 
mortality.  
In interpreting our data, the possibility of confounding through urinary protein losses must 
also be considered. Indeed, Study 4 demonstrates the complexity of proximal tubular 
endocytotic receptor expression, which suggests that the amount of albumin in the urine 
must reflect multiple pathologies that may or may not affect circulating biomarkers.  
Prevalent HD patients in Study 3 unlikely have residual renal function, therefore the results 
obtained in Study 3 were neither qualitatively nor quantitatively different from those 
obtained in the other cohorts, this may suggest that other factors than proximal tubular 
metabolism are more important for their predicative ability. However, this does not mean 
that they reflect the actual pathophysiological processes that drive mortality in the CKD 
population. Indeed, one can argue that the poor performance of all the markers in the 
studies suggests that we still have to elucidate real risk factors. 
 
4.3 The prediction of IL-6  
Of those markers that remained significant predictors after adjustments for basic 
demographic factors and eGFR, IL-6 stands out. In Study 2, an IL-6 concentration above the 
ROC-calculated cut-off (7.0 and 6.7 pg/ml respectively) was classify of baseline CVD (RR=1.10, 
95% CI: 1.02 - 1.19, p=0.01) and predictive of all-cause 5 years mortality (RR=1.79, 95% CI: 
1.20 - 2.67, p=0.01). Likewise, in Study 3 an IL-6 concentration above the ROC-calculated cut-
off (8.3 pg/ml) predicted 5 years CVD-related mortality (RR=2.80, 95% CI: 1.34 - 5.87, 
p=0.006). 
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These findings confirm several previous reports [127, 144]. One may speculate that links 
between IL-6 and the premature ageing phenotype in uremia could be one reason that 
explains why IL-6 has a notable strong performance as risk predictor in patients with CKD. 
Uremic toxins are thought to mediate premature ageing via driving vascular smooth muscle 
cell damage [145] and phenotypic changes [76] and these changes involve IL-6. 
 
4.4 Pentosidine and 8-OH-dG performed better than peptide biomarkers 
In Study 1, we performed an analysis of plasma pentosidine. Pentosidine is a combined AGE-
protein complex [109] which is reported to related with inflammation and malnutrition [107], 
as well as with CVD and poor clinical outcomes [146, 147]. But the contribution of 
pentosidine to the development of cardiovascular events and mortality in CKD patients has 
been disputed [148] and traditional risk factors reported to be more important for 
cardiovascular outcomes in this population [149]. Our data does not address the issue of 
importance as a long-term risk factor, but does show that an elevated plasma pentosidine 
measured in 746 patients with different stages of CKD (some on PD and HD) does predict 
both all-cause and cardiovascular mortality over 5 years follow-up. 
Plasma pentosidine was corrected for serum albumin, but despite this, the pentosidine 
levels were higher in CKD stage 5 patients (who are usually hypoalbuminemic) and 
correlated negatively with eGFR CKD-EPI. In GENMOD, a 1-SD higher pentosidine/albumin 
independently predicted all-cause mortality (RR=1.04; 95% CI: 1.01 - 1.08, p=0.01) and CVD 
mortality (RR=1.03; 95% CI: 1.01 - 1.06, p=0.03) also after adjusting for confounders. As a 
comparison, 1-SD higher age was associated with a predicted increase in all-cause mortality 
(RR=1.08, 95% CI: 1.04 - 1.11, p<0.001) and did not predict CVD mortality (RR=1.01, 95% CI: 
0.98 - 1.05, p=0.22) after adjusting for confounders.  
Thus, plasma pentosidine/albumin was a more useful marker of CVD mortality than age in 
this cohort, while both were associated with similar increases in risk for all-cause mortality. 
This does not mean that plasma pentosidine/albumin can replace demographic parameters. 
Indeed, while we adjusted for the eGFR based cohorts, our analysis in Study 1 did not adjust 
for eGFR itself. As serum albumin tends to decrease and protein pentosidine increases as 
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GFR falls, we may have inadvertently measured something reflecting the risk of declining 
renal function along with pentosidine. 
Another marker that performed well in Study 1 and 3 was the oxidative stress marker 8-OH-
dG, which is the most abundant oxidative product of nucleic acids [111]. In Study 1, 8-OH-dG 
was also an independent predictor of all-cause mortality (RR=1.04, 95% CI: 1.01 - 1.09, 
p=0.03) along with age, pentosidine, baseline CVD, DM and malnutrition. However, 8-OH-dG 
did not significantly predict CVD mortality (RR=1.03, 95% CI: 0.99 - 1.06, p=0.06) after 
adjustments. A similar result was obtained in Study 3: all-cause mortality in 224 prevalent 
HD patients was predicted by amongst others 8-OH-dG (above vs. below 1.35 ng/ml, 
RR=1.56, 95% CI: 1.02 - 2.36, p=0.04) also after adjustments. Again, 8-OH-dG did not 
significantly predict CVD-related mortality (RR=1.74, 95% CI: 0.91 - 3.31, p=0.09). 
Comparing pentosidine to 8-OH-dG, both are thought to reflect increased oxidative stress 
[108, 111] and have been reported to be associated with mortality risk in CKD previously 
[110, 112]. Also, previous data suggests that enhanced production and accumulation of 
pentosidine among patients with impaired renal function is mainly related to conditions 
other than hyperglycaemia [108], possibly because protein glycation is diminished in uremia 
[142]. Thus, levels of AGEs in circulation and in tissues such as skin, in patients with more 
advanced CKD are influenced by factors such as oxidative stress, inflammation and 
decreased renal clearance rather than hyperglycemia [150]. Indeed, the similar performance 
of both 8-OH-dG and pentosidine, including an independent effect of pre-existing DM, 
suggests that it is the molecular size and likely the connection to oxidative damage that is 
most important. 
Plasma pentosidine is usually found attached to protein amino acids and it is therefore 
unclear why it performed better in our studies than did other protein biomarkers (such as 
CRP). One hypothesis is that the combined measurement of free and protein bound 
pentosidine corrected for the confounding of declining GFR. But it is also possible that 
pentosidine more accurately reflects the pathophysiological pathways involved in uremic 
CKD than do for example CRP. 
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4.5 Proximal tubular endocytosis is unchanged in highly albuminuric states 
In Study 4, we investigated mechanisms of importance for circulating peptides in the form of 
endocytic receptors. These receptors, megalin and cubilin, are thought to mediate most re-
uptake of freely filtered protein [9]. Their function and regulation in albuminuric states is 
poorly investigated. Supporting a complex relationship between circulating protein, 
albuminuria and proximal tubular health we report that nephrotic albuminuric states are 
characterized by an expression of megalin that is significantly lower than in micro-
albuminuric states and approaches that in healthy kidneys. While, the expression of cubilin 
increases in all patients compared to living donors. In Study 4, we did not measure activity of 
the receptors, but the ratio of membrane bound to cytoplasmic megalin and cubilin was 
relatively stable between the groups. We can thus speculate that pathologic or protective 
downregulation of megalin occurs in the nephrotic tubule, leading to reduced endocytosis 
and increased urinary losses. This has implications primarily for larger molecules with a 
limited distribution volume. 
 
4.6 Consequences for current therapies 
Each of the investigated risk biomarkers has been demonstrated to independently predict 
both clinical CVD and mortality in various populations across the world. To this list we now 
added pentosidine, which in Study 1 independently predicted all-cause mortality in a large 
cohort of CKD patients. However, as illustrated in Study 2, where we investigated 12 
biomarkers in 543 incident CKD patients starting dialysis, as well as in Study 3 of 224 
prevalent HD patients, the predictive value of even the best biomarkers may be statistically 
significant but are rarely of clinical relevance. Notably the relative risk ratios for baseline 
CVD is usually predicted almost as well using only demographic factors such as age and DM 
(Study 2 and 3). The same holds true for CVD-related and all-cause mortality, although these 
outcomes are currently hard to predict using any method.  
As reviewed by Zoccali et al. [151] many biomarkers have been tested in the dialysis 
population, including ferritin [152], hsCRP [68, 153-156], IGF-1 [49, 72], IL-6 [68, 156, 157], 
sICAM-1, sVCAM-1 [158, 159], TnT [160], TNF-α [161], PLT [162] and WBC [163]. Kalantar-
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Zadeh [119] counted more than 40 published peptide markers of inflammation that are 
elevated in CKD, and many of them correlated with outcomes as well. The present thesis 
suggests that CKD per se may cause as yet undefined far-reaching and systematic alterations 
that appear not to be well reflected by the circulating proteome, either before or after 
staring dialysis. Indeed, our mechanistic studies suggest that a high degree of albuminuria 
happens when the amount of endocytotic receptors available for uptake of proteins in the 
proximal tubules is reduced. Clearly, to identify better biomarkers, future studies should 
attempt to better elucidate and study the pathophysiological pathways specific to CKD 
patients. 
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Chapter 5  Future perspectives 
The structured epidemiological assessment of mortality risk was greatly facilitated when in 
year 2002 a standardized definition and staging of CKD was first proposed [164]. Soon after, 
the degree to which the loss of renal function contributes to increased mortality risk became 
clear [165].  
Since then much effort has been expended in identifying risk factors and biomarkers that 
could both allow more informed choices regarding therapies but also offer clues as to the 
pathophysiological mechanisms behind the increase in risk. After concluding that the 
traditional Framingham risk factors are relatively poor predictors of death in CKD [166] a lot 
of investigations have looked at the predictive power of less established risk markers, mainly 
circulating proteins.  
The present thesis tries to link the performance of some of these many markers to proximal 
tubular renal function. However, we are unable to demonstrate a clear significance of this 
pathway. This suggests that another, so far elucidated, mechanism is behind the mortality 
increase while the observed biomarkers and demographic factors are merely minor 
modifiers. 
Clearly, future studies must aim to go beyond what has been done previously and look with 
fresh eyes at what drives the mortality. In this regard, it is good to focus on systems that 
involve most cells in the body as most physiological processes seem affected in CKD.
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